Fig 5 - by Irene D. Alabia (9191801)

Table_2_A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening.DOCX by Chi C. Tong (5547002)

“…As she has a heterozygous genotype and considered having decreased DPD activity, we followed the international recommendation and restart chemotherapy with at least 50% reduction for 5-FU dose. …”

Table_1_A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening.DOCX by Chi C. Tong (5547002)

“…As she has a heterozygous genotype and considered having decreased DPD activity, we followed the international recommendation and restart chemotherapy with at least 50% reduction for 5-FU dose. …”

Access to the Peripheral Circulation Is Required for Viral Persistence in the Simulation by Karen A Duca (80676)

“…Small incremental decreases below 50% immunosuppression resulted in clearance of Vir similar to that seen in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.0030137#ppat-0030137-g005" target="_blank">Figure 5</a>A.…”

Table_1_Electrical bioimpedance measurement and near-infrared spectroscopy in pediatric postoperative neurocritical care: a prospective observational study.DOCX by Chenhao Wang (6940226)

“…DC was derived from impedance analysis of 0.1 mA–50 kHz current via temporal electrodes. rSO₂ was the percentage of oxyhemoglobin measured from reflected NIR light on the forehead. …”

Effect of costunolide and BIBR1532 on AFP secretion by HepG2/C3A and PLC/PRF/5 cell lines. by Roula Tahtouh (714734)

“…(A) Costunolide (5–50 μM) significantly decreased AFP production in a dose-dependent manner in the supernatants of HepG2/C3A cells after 48 h of treatment, whereas 50 μM costunolide decreased the AFP levels in the supernatant of PLC/PRF/5 cells. …”

Canopy and understory nitrogen addition have different effects on fine root dynamics in a temperate forest: implications for soil carbon storage by Xiaowei Li (7283048)

“…<p>Ÿ Here, we conducted a field experiment comparing the effects of canopy addition of N (CAN) with understory addition of N (UAN) at three N-addition rates (0, 25, and 50 kg N ha^–¹ yr^–¹) on fine root dynamics in a temperate deciduous forest.…”

table3_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

image2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

image1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table5_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table4_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

Assessing and Responding to Palliative Care Needs in Rural Sub-Saharan Africa: Results from a Model Intervention and Situation Analysis in Malawi by Michael E. Herce (644037)

“…</p><p>Conclusions</p><p>We identified a high prevalence of pain and psychosocial needs among patients with serious chronic illnesses in rural Malawi. …”

Datasheet1_Cardioprotective effects of shock wave therapy: A cardiac magnetic resonance imaging study on acute ischemia-reperfusion injury.pdf by Lorena Petrusca (13783213)

“…</p>Discussion<p>In conclusion, we showed in an ischemia-reperfusion open-chest swine model that SW therapy, when applied near the relief of 50′ LAD occlusion, led to a nearly immediate cardioprotective effect translating to a reduction in the acute ischemia-reperfusion lesion size and to a significant LV function improvement. …”

Image_4_A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome.tif by Liuting Zeng (8959880)

Image2_Tourniquet application in primary total knee arthroplasty for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.tif by Jinchang Han (14335419)

“…</p>Methods<p>Two authors independently retrieved PubMed, Embase, and CENTRAL to identify eligible randomized controlled trials (RCTs) evaluating the effectiveness of a tourniquet in TKA. Fixed- (I²< 50%) or random-effects (I²> 50%) models were selected to perform meta-analysis according to the value of I². …”

Table1_Tourniquet application in primary total knee arthroplasty for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.doc by Jinchang Han (14335419)

“…</p>Methods<p>Two authors independently retrieved PubMed, Embase, and CENTRAL to identify eligible randomized controlled trials (RCTs) evaluating the effectiveness of a tourniquet in TKA. Fixed- (I²< 50%) or random-effects (I²> 50%) models were selected to perform meta-analysis according to the value of I². …”

Image1_Tourniquet application in primary total knee arthroplasty for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.tif by Jinchang Han (14335419)

“…</p>Methods<p>Two authors independently retrieved PubMed, Embase, and CENTRAL to identify eligible randomized controlled trials (RCTs) evaluating the effectiveness of a tourniquet in TKA. Fixed- (I²< 50%) or random-effects (I²> 50%) models were selected to perform meta-analysis according to the value of I². …”